Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study

xlomafota13 shared this article with you from Inoreader Surgery of small bowel melanoma metastases in the era of efficient medical therapies: a retrospective cohort study Via Melanoma Research - Published Ahead-of-Print Surgery of small bowel melanoma metastases has to be reconsidered in the era of targeted treatments and immunotherapy. To retrospectively assess context and outcomes of small bowel melanoma metastases resections. All consecutive melanoma patients who underwent resection of small bowel metastases betwee n 2011 and 2017, in a single referral center, were retrospectively analyzed through melanoma-specific survival (MSS). A total of 20 patients were included with a 47.8 months median follow-up. Before small bowel surgery, eight patients (40%) were asymptomatic while seven had anemia and five patients had abdominal pain. All resections were decided on tumor boards except for three surgeries performed in the emergency setting. In the whole cohort, MSS was 89.5 months with 50% of patients alive at the study endpoint. We classified surgical indications in three groups: (1) surgery as a pivotal treatment for mono- or oligo-metastases limited to the small bowel (n = 6); (2) salvage surgery for symptomatic patients in order to preserve their chances to switch to an active line of medical treatment (n = 8); and (3) surgery of small bowel dissociated metastatic progression for patients otherwise controlled (n = 6), aiming at keeping patients with the same treatment or active fo llow-up. In these three situations, the objective of surgery was usually met, and most patients had a long median MSS after surgery: 70.3 months, 89.5 months and 72.4 months, respectively. Although medical treatments have dramatically improved survival in metastatic melanoma, surgical control of life-threatening localization like small bowel metastases is often a condition for long survival. * Nausicaa Malissen and Georges Farvacque contributed equally to the writing of this article. Received 13 October 2020 Accepted 17 March 2021 Correspondence to Nausicaa Malissen, MD, PhD, Dermatology and Skin Cancer Department, Hôpital La Timone, 278 rue Saint-Pierre, 13005 Marseille, France, Tel: +33 4 91 38 75 98; fax +33 4 91 38 79 89; e-mail: nausicaa.malissen@ap-hm.fr Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.